JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

Inclusion Criteria: * Sign the informed consent form, voluntarily participate in this study, good compliance and follow-up cooperation. * Histologically or pathologically confirmed unresectable hepatocellular carcinoma; * Male or female patients aged 18-75 years; * Eastern Cooperative Oncology Group (ECOG) PS score of 0-1; * Child-Pugh score of ≤7; * BCLC/B stage; not previously treated with anti-cancer therapy; at least one measurable lesion (according to RECIST 1.1 criteria). * Sufficient organ function in vital organs (excluding serious functional impairment in the heart, lung, liver, kidney, bone marrow, nervous system, and endocrine systems). Exclusion Criteria: * Diagnosed with fibrolamellar carci-noma of liver, intrahepatic cholangiocarcinoma, and mixed carcinoma; * Within 28 days prior to the start of the study, the participant received treatment with another investigational drug or participated in another clinical study for a different therapeutic indication.; * Based on the investigator's judgment, the patient is expected to live for less than 12 weeks; * Uncontrolled pleural effusion, pericardial effusion, or ascites of moderate volume or more; * Current or past history of central nervous system metastasis; * Have a history of psychotropic drug abuse or drug use; * Hereditary or acquired tendency towards bleeding and thrombosis, a thromboembolic event occurred within the past 6 months; * Have a history of severe allergy to any monoclonal antibody, Toripalimab , JS014 and other ingredients of this study; * Pregnant or breastfeeding women; * Subjects with other factors that, in the judgment of the investigator, may cause the study to be prematurely terminated.